These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 17138674)
21. Treprostinil for the treatment of pulmonary arterial hypertension. Torres F; Rubin LJ Expert Rev Cardiovasc Ther; 2013 Jan; 11(1):13-25. PubMed ID: 23259441 [TBL] [Abstract][Full Text] [Related]
22. Impact of switching from epoprostenol to IV treprostinil on treatment satisfaction and quality of life in patients with pulmonary hypertension. Minai OA; Parambil J; Dweik RA; Davila GH; Peterson L; Rollins KD; Chen H Respir Med; 2013 Mar; 107(3):458-65. PubMed ID: 23266038 [TBL] [Abstract][Full Text] [Related]
23. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262 [TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. Channick RN; Olschewski H; Seeger W; Staub T; Voswinckel R; Rubin LJ J Am Coll Cardiol; 2006 Oct; 48(7):1433-7. PubMed ID: 17010807 [TBL] [Abstract][Full Text] [Related]
25. Oral treprostinil for the treatment of pulmonary arterial hypertension. de Lartigue J Drugs Today (Barc); 2014 Aug; 50(8):557-65. PubMed ID: 25187906 [TBL] [Abstract][Full Text] [Related]
26. Initial experience using continuous intravenous treprostinil to manage pulmonary arterial hypertension in patients with end-stage liver disease. Sakai T; Planinsic RM; Mathier MA; de Vera ME; Venkataramanan R Transpl Int; 2009 May; 22(5):554-61. PubMed ID: 19175541 [TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Tapson VF; Gomberg-Maitland M; McLaughlin VV; Benza RL; Widlitz AC; Krichman A; Barst RJ Chest; 2006 Mar; 129(3):683-8. PubMed ID: 16537868 [TBL] [Abstract][Full Text] [Related]
28. Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension--seven sites, United States, 2003-2006. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2007 Mar; 56(8):170-2. PubMed ID: 17332729 [TBL] [Abstract][Full Text] [Related]
33. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Tapson VF; Torres F; Kermeen F; Keogh AM; Allen RP; Frantz RP; Badesch DB; Frost AE; Shapiro SM; Laliberte K; Sigman J; Arneson C; Galiè N Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490 [TBL] [Abstract][Full Text] [Related]
34. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. Hiremath J; Thanikachalam S; Parikh K; Shanmugasundaram S; Bangera S; Shapiro L; Pott GB; Vnencak-Jones CL; Arneson C; Wade M; White RJ; J Heart Lung Transplant; 2010 Feb; 29(2):137-49. PubMed ID: 20022264 [TBL] [Abstract][Full Text] [Related]
35. Inhaled treprostinil sodium for the treatment of pulmonary arterial hypertension. Ferrantino M; White RJ Expert Opin Pharmacother; 2011 Nov; 12(16):2583-93. PubMed ID: 21988216 [TBL] [Abstract][Full Text] [Related]
36. Treprostinil: new drug. Pulmonary artery hypertension: just another (disappointing) prostacycline analogue. Prescrire Int; 2006 Oct; 15(85):177-9. PubMed ID: 17128524 [TBL] [Abstract][Full Text] [Related]
37. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Tapson VF; Jing ZC; Xu KF; Pan L; Feldman J; Kiely DG; Kotlyar E; McSwain CS; Laliberte K; Arneson C; Rubin LJ; Chest; 2013 Sep; 144(3):952-958. PubMed ID: 23669822 [TBL] [Abstract][Full Text] [Related]
38. Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertension. Skoro-Sajer N; Bonderman D; Wiesbauer F; Harja E; Jakowitsch J; Klepetko W; Kneussl MP; Lang IM J Thromb Haemost; 2007 Mar; 5(3):483-9. PubMed ID: 17319903 [TBL] [Abstract][Full Text] [Related]
39. Successful management of an acute subdural hematoma in a patient dependent on continuous treprostinil infusion therapy. Safain M; Shepard M; Rahal J; Kryzanski J; Hwang S; Roguski M; Riesenburger RI J Neurosurg; 2013 Apr; 118(4):753-6. PubMed ID: 23373804 [TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Jing ZC; Parikh K; Pulido T; Jerjes-Sanchez C; White RJ; Allen R; Torbicki A; Xu KF; Yehle D; Laliberte K; Arneson C; Rubin LJ Circulation; 2013 Feb; 127(5):624-33. PubMed ID: 23307827 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]